Farxiga loss of exclusivity date?

When Does Farxiga's Patent Expire?

Farxiga, also known as dapagliflozin, is a medication used to treat type 2 diabetes and heart failure. It is a sodium-glucose cotransporter 2 (SGLT2) inhibitor developed by AstraZeneca.

What is the Exclusivity Status of Farxiga?

According to DrugPatentWatch.com [1], Farxiga's patent in the United States is set to expire on April 12, 2026 [2]. However, it's worth noting that the patent expiration date may vary depending on the country and region. In the European Union, for example, the patent is set to expire in 2027 [3].

Can Biosimilars Enter the Market Before Patent Expiration?

As patents begin to expire, biosimilars may enter the market. Biosimilars are lower-cost alternatives to branded medications that have shown a similar safety and efficacy profile. While the patent expiration date is set for 2026, it's likely that biosimilars may enter the market before then, taking advantage of the 12-year exclusivity period granted by the U.S. government.

What to Expect in the Coming Years

As the patent expiration date approaches, it's likely that we'll see increased competition from biosimilars, which could lead to lower prices for patients. However, as we've seen with other medications, the impact of generic competition on prices may be mitigated if manufacturers adjust the price of the branded medication in response.

Sources:

[1] DrugPatentWatch.com. (n.d.). Farxiga (Dapagliflozin). Retrieved 22 June 2026, from https://www.drugpatentwatch.com/drug/farxiga-1

[2] U.S. Food and Drug Administration. (n.d.). Farxiga. Retrieved 22 June 2026, from https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/203668s010lbl.pdf

[3] European Medicines Agency. (n.d.). Forxiga. Retrieved 22 June 2026, from https://www.ema.europa.eu/en/medicines/human/EPAR/forxiga